Dasatinib Accord Den europeiske union - norsk - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Den europeiske union - norsk - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Teva 70 mg Norge - norsk - Statens legemiddelverk

dasatinib teva 70 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 70 mg

Dasatinib Teva 20 mg Norge - norsk - Statens legemiddelverk

dasatinib teva 20 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 20 mg

Dasatinib Teva 50 mg Norge - norsk - Statens legemiddelverk

dasatinib teva 50 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 50 mg

Dasatinib Sandoz 70 mg Norge - norsk - Statens legemiddelverk

dasatinib sandoz 70 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 70 mg

Dasatinib Sandoz 20 mg Norge - norsk - Statens legemiddelverk

dasatinib sandoz 20 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 20 mg

Dasatinib Sandoz 50 mg Norge - norsk - Statens legemiddelverk

dasatinib sandoz 50 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 50 mg

Sprycel Den europeiske union - norsk - EMA (European Medicines Agency)

sprycel

bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - sprycel er angitt for behandling av paediatric pasienter med nylig diagnostisert philadelphia kromosom-positiv kronisk myelogen leukemi i kronisk fase (ph+ cml cp) eller ph+ cml cp resistente eller intolerante til før terapi inkludert imatinib. nylig diagnostisert ph+ akutt lymfoblastisk leukemi (all) i kombinasjon med kjemoterapi. sprycel er indisert for behandling av voksne pasienter med nydiagnostisert philadelphia-kromosom-positive (ph+) kronisk myelogen leukemi (cml) i den kroniske fasen;kronisk, akselerert eller sprenge fase kml med resistens eller intoleranse overfor tidligere behandling inkludert imatinib mesilate;ph+ akutt lymfoblastisk leukemi (all) og lymfoide blast cml med resistens eller intoleranse overfor tidligere behandling. sprycel er angitt for behandling av paediatric pasienter med nylig diagnostisert ph+ kml i kronisk fase (ph+ cml-cp) eller ph+ cml-cp resistente eller intolerante til før terapi inkludert imatinib.

Sprycel 20 mg Norge - norsk - Statens legemiddelverk

sprycel 20 mg

abacus medicine a/s - dasatinibmonohydrat - tablett, filmdrasjert - 20 mg